microbial drug resistance

Summary

Summary: The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS).

Top Publications

  1. ncbi Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea
    H J Cheong
    Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
    Clin Infect Dis 33:48-53. 2001
  2. ncbi Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients
    Joshua P Metlay
    Philadelphia Veterans Affairs Medical Center, University of Pennsylvania School of Medicine, 712 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Gen Intern Med 17:87-94. 2002
  3. ncbi The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
    D J Austin
    Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom
    Proc Natl Acad Sci U S A 96:1152-6. 1999
  4. ncbi Vaccine escape recombinants emerge after pneumococcal vaccination in the United States
    Angela B Brueggemann
    Department of Zoology, University of Oxford, Oxford, United Kingdom
    PLoS Pathog 3:e168. 2007
  5. ncbi Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
    M A Ghannoum
    Center for Medical Mycology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Clin Microbiol Rev 12:501-17. 1999
  6. ncbi Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
    T C White
    Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle Biomedical Research Institute, Washington, USA
    Clin Microbiol Rev 11:382-402. 1998
  7. ncbi Predicting the emergence of antibiotic resistance by directed evolution and structural analysis
    M C Orencia
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Nat Struct Biol 8:238-42. 2001
  8. ncbi A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA
    Subray S Hegde
    Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Science 308:1480-3. 2005
  9. ncbi Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries
    M A Espinal
    World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
    JAMA 283:2537-45. 2000
  10. ncbi Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network
    L McGee
    MRC SAIMR Wits Pneumococcal Diseases Research Unit, Johannesburg, South Africa
    J Clin Microbiol 39:2565-71. 2001

Detail Information

Publications189 found, 100 shown here

  1. ncbi Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea
    H J Cheong
    Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
    Clin Infect Dis 33:48-53. 2001
    ..Therefore, the isolates revealed little evidence of clonal spread and may have emerged in direct response to the selective pressure exerted by prior fluoroquinolone use...
  2. ncbi Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients
    Joshua P Metlay
    Philadelphia Veterans Affairs Medical Center, University of Pennsylvania School of Medicine, 712 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, USA
    J Gen Intern Med 17:87-94. 2002
    ..However, optimal use from the perspective of the community (reserving newer agents for future use) is not always consistent with optimal use from the perspective of the individual patient (prescribing newer, broader agents)...
  3. ncbi The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance
    D J Austin
    Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, South Parks Road, Oxford OX1 3PS, United Kingdom
    Proc Natl Acad Sci U S A 96:1152-6. 1999
    ..These results highlight the need for early intervention once resistance is detected...
  4. ncbi Vaccine escape recombinants emerge after pneumococcal vaccination in the United States
    Angela B Brueggemann
    Department of Zoology, University of Oxford, Oxford, United Kingdom
    PLoS Pathog 3:e168. 2007
    ..Vaccine escape by genetic recombination at the capsular locus has the potential to reduce PCV7 effectiveness in the longer term...
  5. ncbi Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
    M A Ghannoum
    Center for Medical Mycology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Clin Microbiol Rev 12:501-17. 1999
    ..For example, modification of enzymes which serve as targets for antimicrobial action and the involvement of membrane pumps in the extrusion of drugs are well characterized in both the eukaryotic and prokaryotic cells...
  6. ncbi Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
    T C White
    Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle Biomedical Research Institute, Washington, USA
    Clin Microbiol Rev 11:382-402. 1998
    ..Since the study of antifungal drug resistance is relatively new, other factors that may also contribute to resistance are discussed...
  7. ncbi Predicting the emergence of antibiotic resistance by directed evolution and structural analysis
    M C Orencia
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Nat Struct Biol 8:238-42. 2001
    ..Our results demonstrate that directed evolution coupled with structural analysis can be used to predict future mutations that lead to increased antibiotic resistance...
  8. ncbi A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA
    Subray S Hegde
    Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Science 308:1480-3. 2005
    ..This represents a form of DNA mimicry and explains both its inhibitory effect on DNA gyrase and fluoroquinolone resistance resulting from the protein's expression in vivo...
  9. ncbi Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries
    M A Espinal
    World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
    JAMA 283:2537-45. 2000
    ....
  10. ncbi Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network
    L McGee
    MRC SAIMR Wits Pneumococcal Diseases Research Unit, Johannesburg, South Africa
    J Clin Microbiol 39:2565-71. 2001
    ..This network can serve as a prototype for the collaboration of scientists in identifying clones of important human pathogens and as a model for the development of other networks...
  11. ncbi Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide
    Y Zhang
    Department of Molecular Microbiology and Immunology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205
    J Bacteriol 181:2044-9. 1999
    ..tuberculosis to PZA and that the natural PZA resistance of M. smegmatis is due to a highly active efflux pump. These findings may have implications with regard to the design of new antimycobacterial drugs...
  12. ncbi Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 406:959-64. 2000
    ..We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances...
  13. ncbi Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000
    Clyde Thornsberry
    Focus Technologies Inc, Nashville, TN, USA. answers.com
    Clin Infect Dis 34:S4-S16. 2002
    ..6%) and M. catarrhalis (86.2%-96.8%) also varied by region. Notable variation in regional antimicrobial resistance rates (S. pneumoniae) and beta-lactamase production (H. influenzae, M. catarrhalis) exists throughout the United States...
  14. ncbi Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones
    L Ferrero
    Departement des Biotechnologies, Rhone Poulenc Rorer S A, Centre de Recherche de Vitry Alfortville, Vitry sur Seine, France
    Mol Microbiol 13:641-53. 1994
    ..coli GyrA, is substituted to Phe or Tyr in both high- and low-quinolone-resistant isolates. We propose that DNA topoisomerase IV is a primary target of fluoroquinolones in S. aureus...
  15. ncbi Pentapeptide repeat proteins
    Matthew W Vetting
    Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    Biochemistry 45:1-10. 2006
    ..MfpA binds to DNA gyrase and inhibits its activity. The rod-shaped, dimeric protein exhibits remarkable similarity in size, shape, and electrostatics to DNA...
  16. ncbi A novel family of potentially mobile DNA elements encoding site-specific gene-integration functions: integrons
    H W Stokes
    School of Biological Sciences, Macquarrie University, Sydney, NSW, Australia
    Mol Microbiol 3:1669-83. 1989
    ..This family of elements appears formally distinct from other known mobile DNA elements and we propose the name DNA integration elements, or integrons...
  17. ncbi Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
    Ari Robicsek
    Harvard Medical School, Division of Infectious Diseases, Massachusetts General Hospital, 55 Fruit St, GRJ 512, Boston, Massachusetts 02114, USA
    Nat Med 12:83-8. 2006
    ....
  18. ncbi Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention
    J C Butler
    Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Vaccine 16:1693-7. 1998
    ..However, the vaccine is underutilized, and a substantial reduction in the morbidity and mortality associated with invasive pneumococcal infections is unlikely until the vaccine is used more widely among persons at risk for disease...
  19. ncbi Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA
    C Montero
    , , Instituto de Investigaciones Cientificas (IVIC, Caracas 1020A, Venezuela
    Antimicrob Agents Chemother 45:3387-92. 2001
    ..smegmatis mutant strain lacking an intact mfpA gene than for the WT strain, suggesting that, by some unknown mechanism, the gene product plays a role in determining the innate level of FQ(R) in M. smegmatis...
  20. ncbi Veterinary drug usage and antimicrobial resistance in bacteria of animal origin
    Frank M Aarestrup
    Danish Institute for Food and Veterinary Research, Copenhagen V, Denmark
    Basic Clin Pharmacol Toxicol 96:271-81. 2005
    ..Programmes monitoring the occurrence and development of resistance and consumption of antimicrobial agents are strongly desirable, as is research into the most appropriate ways to use antimicrobial agents in veterinary medicine...
  21. ncbi AcrAB and related multidrug efflux pumps of Escherichia coli
    H Nikaido
    Department of Molecular and Cell Biology, University of California, Berkeley 94720 3206, USA
    J Mol Microbiol Biotechnol 3:215-8. 2001
    ..It forms a trimer that interacts with a monomeric AcrB, which was shown by in vitro reconstitution to be a proton antiporter. Details of interaction between the..
  22. ncbi Molecular analysis of antibiotic resistance gene clusters in vibrio cholerae O139 and O1 SXT constins
    B Hochhut
    Division of Geographic Medicine/Infectious Diseases, New England Medical Center, Tufts University School of Medicine, and Howard Hughes Medical Institute, Boston, Massachusetts 02111, USA
    Antimicrob Agents Chemother 45:2991-3000. 2001
    ..These studies indicate that there is considerable flux in the antibiotic resistance genes found in the SXT family of constins and point to a model for the evolution of these related mobile elements...
  23. ncbi Transient intestinal carriage after ingestion of antibiotic-resistant Enterococcus faecium from chicken and pork
    T L Sørensen
    Department of Microbiological Research and Development, Statens Serum Institut, Copenhagen, Denmark
    N Engl J Med 345:1161-6. 2001
    ..Antibiotic-resistant enterococci are often present in retail meats, but it is unclear whether the ingestion of these contaminants leads to sustained intestinal carriage...
  24. ncbi Comparison of SXT and R391, two conjugative integrating elements: definition of a genetic backbone for the mobilization of resistance determinants
    J W Beaber
    Division of Geographic Medicine/Infectious Diseases, New England Medical Center, NEMC 041, 750 Washington St, Boston, Massachusetts 02111, USA
    Cell Mol Life Sci 59:2065-70. 2002
    ..This backbone represents a scaffold for the mobilization of genetic material between a wide range of gram-negative bacteria, allowing for rapid adaptation to changing environments...
  25. ncbi Campylobacter jejuni Infections: update on emerging issues and trends
    B M Allos
    Department of Preventive Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Infect Dis 32:1201-6. 2001
    ..jejuni infection, but its incidence is <1 per 1000 infections. Careful food preparation and cooking practices may prevent some Campylobacter infections...
  26. ncbi In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi
    K P Hunfeld
    Institute of Medical Microbiology, University Hospital of Frankfurt, Paul Ehrlich Strasse 40, 60596 Frankfurt Main, Germany
    Int J Antimicrob Agents 17:203-8. 2001
    ..burgdorferi complex. The excellent in vitro effectiveness of acylamino-penicillin derivatives and their suitability for the therapy of Lyme disease is emphasised...
  27. ncbi Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli
    R Bachoual
    , Centre Hospitalier Universitaire Henri Mondor, , France
    Microb Drug Resist 7:257-61. 2001
    ..In contrast with the results obtained with clinical isolates, a variety of gyrA mutations were obtained in vitro...
  28. ncbi Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria
    C Freiberg
    Institute for Anti infectives Research, Pharma Research, Bayer AG, Wuppertal, Germany
    J Mol Microbiol Biotechnol 3:483-9. 2001
    ..These findings demonstrate the potential of such proteins to be used in screening of large chemical libraries for inhibitors which could be further developed to novel broad-spectrum antibiotics...
  29. ncbi Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom
    E J Threlfall
    Central Public Health Laboratory, London, United Kingdom
    Emerg Infect Dis 7:448-50. 2001
    ..Increasing numbers of treatment failures have been noted. Most infections have been in patients with a recent history of travel to India and Pakistan...
  30. ncbi A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-Amino-4-deoxy-L-arabinose. Identification and function oF UDP-4-deoxy-4-formamido-L-arabinose
    Steven D Breazeale
    Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biol Chem 280:14154-67. 2005
    ..Because the L-Ara4N unit attached to lipid A is not derivatized with a formyl group, we postulate the existence of a deformylase, acting later in the pathway...
  31. ncbi Horizontal transfer of a multi-drug resistance plasmid between coliform bacteria of human and bovine origin in a farm environment
    H Oppegaard
    Department of Pharmacology, Microbiology, and Food Hygiene, The Norwegian School of Veterinary Science, N 0033 Oslo, Norway
    Appl Environ Microbiol 67:3732-4. 2001
    ..Isolates from both cattle and humans harbored an R plasmid of 65 kb (pTMS1) that may have been transferred between them due to selective antibiotic pressure in the farm environment...
  32. ncbi Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315
    Toshiko Ohta
    Institute of Basic Medical Sciences, University of Tsukuba, 1 1 1 Tennohdai, Tukuba, Ibaraki 305 8575, Japan
    DNA Res 11:51-6. 2004
    ..All of the diverse genes and the high quality sequence of Mu50 can be viewed at the web site (http://133.5.48.239/VRSA/)...
  33. ncbi The impact of antimicrobial resistance on health and economic outcomes
    Sara E Cosgrove
    Division of Infectious Disease, Johns Hopkins Hospital, Baltimore, MD, USA
    Clin Infect Dis 36:1433-7. 2003
    ....
  34. ncbi Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin
    R Leclercq
    CHU de Caen, Service de Microbiologie, Avenue Cote de Nacre, 14033 Caen Cedex, France
    J Antimicrob Chemother 48:9-23. 2001
    ..Telithromycin therefore represents an important addition to the therapeutic armamentarium in an era of increasing antimicrobial resistance, with an expected low likelihood of the development of resistance in clinical use...
  35. ncbi Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria
    H Nikaido
    Department of Molecular and Cell Biology, University of California, 229 Stanley Hall, Berkeley, CA 94720 3206, USA
    Semin Cell Dev Biol 12:215-23. 2001
    ....
  36. ncbi Mechanisms of resistance to antibiotics
    Gerard D Wright
    Department of Biochemistry, McMaster University, 1200 Main St W, Hamilton, Ontario L8N 3Z5, Canada
    Curr Opin Chem Biol 7:563-9. 2003
    ....
  37. ncbi The crystal structure of the outer membrane protein VceC from the bacterial pathogen Vibrio cholerae at 1.8 A resolution
    Luca Federici
    Department of Biochemistry, University of Cambridge, United Kingdom
    J Biol Chem 280:15307-14. 2005
    ..Our analyses of the external surfaces of VceC and other channel proteins suggest that different classes of efflux pumps have distinct architectures. We discuss the implications of these findings for mechanisms of drug and protein export...
  38. ncbi Treatment of isoniazid-resistant tuberculosis in southeastern Texas
    P Escalante
    Sections of Pulmonary and Critical Care, Institute for the Study of Human Bacterial Pathogenesis, Baylor College of Medicine, Houston, TX, USA
    Chest 119:1730-6. 2001
    ..However, the optimal regimen and duration are unclear. Study objective: To analyze the efficacy of treatment regimens used for INHr-TB in the southeastern Texas region...
  39. ncbi Surveillance of antimicrobial resistance--what, how and whither?
    R Bax
    Biosyn Inc, 3401 Market Street, Philadelphia, PA 19104 6273, USA
    Clin Microbiol Infect 7:316-25. 2001
    ..To express the views of a working party held to consider antibiotic resistance surveillance systems, their strengths and weaknesses, and their current and future applications...
  40. ncbi Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates
    J Engberg
    Department of Gastrointestinal Infections, Division of Diagnostics, Statens Serum Institut, Artillerivej 5, DK 2300 Copenhagen S, Denmark
    Emerg Infect Dis 7:24-34. 2001
    ....
  41. ncbi Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
    M A Kelley
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7030, USA
    Clin Infect Dis 31:1008-11. 2000
    ..Among pneumococci, low-level resistance to macrolides can lead to clinical failure, and resistance to macrolides should be considered during the selection of empiric therapy for patients with presumed pneumococcal infections...
  42. ncbi Vancomycin-intermediate Staphylococcus aureus in Korea
    M N Kim
    Department of Clinical Pathology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea
    J Clin Microbiol 38:3879-81. 2000
    ..The blood culture isolate of MRSA exhibited reduced susceptibility to vancomycin (MIC, 8 microg/ml). This is the first report of a vancomycin-intermediate S. aureus case from Korea...
  43. ncbi Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis
    A E DeBarber
    Tuberculosis Research Section, Laboratory of Host Defenses, National Institutes of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 97:9677-82. 2000
    ..These isolates showed broad cross-resistance to thiocarbonyl containing drugs including ETA, thiacetazone, and thiocarlide...
  44. ncbi A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 405:962-6. 2000
    ..tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis...
  45. ncbi The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America
    Brad Spellberg
    Division of Infectious Diseases, Harbor University of California Los Angeles UCLA Medical Center, Torrance, CA 90502, USA
    Clin Infect Dis 46:155-64. 2008
    ..If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required...
  46. ncbi The rising impact of mathematical modelling in epidemiology: antibiotic resistance research as a case study
    L Temime
    CNAM, Chaire Hygiène and Sécurité, Paris, France
    Epidemiol Infect 136:289-98. 2008
    ..The results of this analysis, which might be applicable to other emerging public health problems, demonstrate the growing interest in mathematical modelling approaches to evaluate antibiotic resistance...
  47. ncbi Efficient targeted mutagenesis in Borrelia burgdorferi
    J L Bono
    Laboratory of Human Bacterial Pathogenesis, National Institute of Allergy and Infectious Disease, National Institutes of Health, Hamilton, Montana 59840, USA
    J Bacteriol 182:2445-52. 2000
    ..The kanamycin resistance marker allows efficient direct selection of mutants in B. burgdorferi and hence is a significant improvement in the ability to construct isogenic mutant strains in this pathogen...
  48. ncbi Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria
    B R Levin
    Department of Biology, Emory University, Atlanta, Georgia 30322, USA
    Genetics 154:985-97. 2000
    ....
  49. ncbi The Rcs phosphorelay is a cell envelope stress response activated by peptidoglycan stress and contributes to intrinsic antibiotic resistance
    Mary E Laubacher
    Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, PA 16802, USA
    J Bacteriol 190:2065-74. 2008
    ..We propose that the Rcs pathway responds to peptidoglycan damage and contributes to the intrinsic resistance of E. coli to beta-lactam antibiotics...
  50. ncbi inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis
    A Banerjee
    Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461
    Science 263:227-30. 1994
    ..These results suggest that InhA is likely a primary target of action for INH and ETH...
  51. ncbi Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria
    P M Bennett
    Bacterial Genetics, University of Bristol, Bristol, UK
    Br J Pharmacol 153:S347-57. 2008
    ..These various aspects of bacterial resistance to antibiotics will be explored in this presentation...
  52. ncbi Biofilm induced tolerance towards antimicrobial peptides
    Anders Folkesson
    Infection Microbiology Group, BioCentrum DTU, Technical University of Denmark, Lyngby, Denmark
    PLoS ONE 3:e1891. 2008
    ....
  53. ncbi Erythromycin resistance genes in group A streptococci of different geographical origins. The Macrolide Resistance Study Group
    J Kataja
    Antimicrobial Research Laboratory, National Public Health Institute, PO Box 57, 20521 Turku, Finland
    J Antimicrob Chemother 46:789-92. 2000
    ..In addition to the mefA gene, the recently sequenced ermTR gene was also widely distributed among isolates of different clonal origin...
  54. ncbi Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis
    R A Slayden
    Tuberculosis Research Section, Twinbrook II, Room 239, Laboratory of Host Defenses, 12441 Parklawn Drive, NIAID, Rockville, MD 20852, USA
    Mol Microbiol 38:514-25. 2000
    ..Nonetheless, INH appeared to resemble TLM more closely in overall mode of action, and KasA levels appeared to be tightly correlated with INH sensitivity...
  55. ncbi Antibiotic resistance in the intensive care unit
    M H Kollef
    Campus Box 8052, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann Intern Med 134:298-314. 2001
    ..Careful, focused attention to this problem at the local ICU level, using a multidisciplinary approach, will have the greatest likelihood of limiting the development and dissemination of antibiotic-resistant infections...
  56. ncbi Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?
    L P Ormerod
    Chest Clinic, Blackburn Royal Infirmary, Blackburn, Lancs, BB2 3LR, UK
    J Infect 42:1-3. 2001
    ..A retrospective clinical study of all patients treated for non-MDR-TB isoniazid-resistant organisms was undertaken...
  57. ncbi Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance
    G H Cassell
    Lilly Research Laboratories, Eli Lilly and Co, Drop Code 0438, LCC, Indianapolis, IN 46285
    JAMA 285:601-5. 2001
    ..Functional genomics and integrative biology should validate these targets and provide the best opportunity for developing effective new therapies, improved diagnostic techniques, and better tools to understand host-pathogen interactions...
  58. ncbi A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment
    Ajit K Sarmah
    Landcare Research New Zealand Limited, Private Bag 3127, Hamilton, New Zealand
    Chemosphere 65:725-59. 2006
    ..The final section highlights some unresolved questions and presents a way forward on issues requiring urgent attention...
  59. ncbi In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus
    P Vaudaux
    Division of Infectious Diseases, University Hospitals of Geneva, CH 1211 Geneva 14, Switzerland
    J Antimicrob Chemother 47:163-70. 2001
    ..aureus subpopulations exhibiting decreased glycopeptide susceptibility and growing in the presence of otherwise inhibitory concentrations of these antimicrobial agents...
  60. ncbi Distribution of mef(A) in gram-positive bacteria from healthy Portuguese children
    Vicki A Luna
    Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Antimicrob Agents Chemother 46:2513-7. 2002
    ..isolate, and an Enterococcus sp. isolate had their mef(A) genes completely sequenced and showed 100% identity at the DNA and amino acid levels with the mef(A) gene from S. pneumoniae...
  61. ncbi The effect of a community intervention trial on parental knowledge and awareness of antibiotic resistance and appropriate antibiotic use in children
    M J Trepka
    Epidemic Intelligence Service, State Branch, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Pediatrics 107:E6. 2001
    ..Overuse of antibiotics for children's upper respiratory infections is widespread and contributes to the emergence of antibiotic-resistant bacteria...
  62. ncbi Invasive pneumococcal disease in England and Wales: vaccination implications
    K Sleeman
    Oxford Vaccine Group, John Radcliffe Hospital, Oxford, United Kingdom
    J Infect Dis 183:239-246. 2001
    ..The data also indicate that IPD varies by serotype, age, and country, emphasizing that the epidemiology of IPD is heterogeneous and requires continued surveillance...
  63. ncbi Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children
    Arthur L Frank
    Department of Pediatrics, College of Medicine, University of Illinois at Chicago, USA
    Pediatr Infect Dis J 21:530-4. 2002
    ..Clindamycin remains a treatment option if the clinician is notified of the risk by the microbiology laboratory and the clinical situation is suitable...
  64. ncbi Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections
    Michael A Pfaller
    CAST Laboratories, University of Iowa College of Medicine, Iowa City, Iowa, USA
    Diagn Microbiol Infect Dis 44:77-84. 2002
    ..catarrhalis in CARTI, and high fluoroquinolone potency/spectrum (>97% susceptible). beta-lactams and macrolides continue to be compromised by increasing resistances in pathogens isolated in these monitored primary care settings...
  65. ncbi In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics
    I Friedland
    Merck Research Laboratories, West Point, PA, USA
    J Chemother 14:483-91. 2002
    ..e., the entire recommended dosing interval, and below the free drug concentration for at least 8 h...
  66. ncbi Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia
    Glenn A Pankuch
    Department of Pathology, Hershey Medical Center, PO Box 850, Hershey, PA 17033, USA
    Antimicrob Agents Chemother 46:2671-5. 2002
    ..The remaining 14 strains were more heterogeneous and had mutations only in parC and/or parE, and the MICs of quinolones were lower for these strains...
  67. ncbi Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications
    F Bert
    Department of Microbiology, Hospital Beaujon, 100 Boulevard du General Leclerc, 92110 Clichy, France
    Eur J Clin Microbiol Infect Dis 22:10-5. 2003
    ..The results indicate that the empirical treatment of spontaneous bacterial peritonitis should differ for nosocomial and community-acquired cases...
  68. ncbi Molecular epidemiology of oxacillin-resistant Staphylococcus aureus in Brooklyn, New York
    D Landman
    Department of Medicine Box 77, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Eur J Clin Microbiol Infect Dis 22:58-61. 2003
    ..Regional infection control strategies may need to be developed to limit the spread of the ORSA clone endemic to this area...
  69. ncbi [New antimicrobial drugs: an update]
    Heinz Burgmann
    Klinische Abteilung für Infektionen und Chemotherapie, Universitätsklinik für Innere Medizin I, Wahringer Gurtel 18 20, A 1090 Wien
    Wien Med Wochenschr 153:166-8. 2003
    ..The following reviews deals with new substances such as carbapenems, quinolones, ketolides, oxazolidinones, glycylcyclines, echinocandines and azoles...
  70. ncbi Multidrug resistance in Serratia marcescens and cloning of genes responsible for the resistance
    Jing Chen
    Department of Microbiology, Faculty of Pharmaceutical Sciences, Okayama University, Tsushima-naka, Japan
    Biol Pharm Bull 26:391-3. 2003
    ..It appears that each class of plasmid carries different types of drug resistance genes. Analysis of such genes will reveal the multiple mechanisms involved in multidrug resistance in S. marcescens...
  71. ncbi The putative response regulator BaeR stimulates multidrug resistance of Escherichia coli via a novel multidrug exporter system, MdtABC
    Satoshi Nagakubo
    Department of Cell Membrane Biology, Institute of Scientific and Industrial Research, Osaka University, Ibaraki shi, Japan
    J Bacteriol 184:4161-7. 2002
    ..A BLAST search suggested that such a heteromultimer-type RND exporter constitutes a unique family among gram-negative organisms...
  72. ncbi Topical ciprofloxacin versus topical gentamicin for chronic otitis media
    O Nawasreh
    Prince Rashid Ben Al-Hasan Hospital, Al-Husn, Jordan
    East Mediterr Health J 7:26-30. 2001
    ..Topical ciprofloxacin is safe and more efficacious and efficient than topical gentamicin in the treatment of acute exacerbation of chronic suppurative otitis media...
  73. ncbi Pharmacological profile of extracts of Pelargonium sidoides and their constituents
    Herbert Kolodziej
    Institut fur Pharmazie, Pharmazeutische Biologie, Freie Universitat Berlin, Berlin, Germany
    Phytomedicine 10:18-24. 2003
    ..The present results, when taken together with the recently reported pharmacological activities, provide for a rationale basis of the utilization of EPs 7630 in the treatment of respiratory tract infections...
  74. ncbi [First choice antibiotics viewed from their characteristics]
    Kazufumi Hiramatsu
    Nippon Naika Gakkai Zasshi 95:2188-92. 2006
  75. ncbi Prevalence of inducible clindamycin resistance in staphylococcal isolates at a Korean tertiary care hospital
    Hwan Sub Lim
    Department of Laboratory Medicine, Kwandong University College of Medicine, Kyunggi, Korea
    Yonsei Med J 47:480-4. 2006
    ..This study indicates importance of the D-zone test in detecting inducible clindamycin resistance in staphylococci to aid in the optimal treatment of patients...
  76. ncbi Synthesis of novel tricyclic oxazolidinones by a tandem SN2 and SNAr reaction: SAR studies on conformationally constrained analogues of Linezolid
    N Selvakumar
    Anti infectives Discovery Group, Discovery Research, Dr Reddy s Laboratories Ltd, Miyapur, Hyderabad, India
    Bioorg Med Chem Lett 16:4416-9. 2006
    ..However, the introduction of fluorine (analogue 34) on the already potent non-fluorine thiocarbamate 21 did not have any influence on the activity...
  77. ncbi Methicillin resistance among Staphylococcus aureus isolates from Saudi hospitals
    Atif H Asghar
    Department of Environmental and Health Research, The Custodian of the Two Holy Mosques Institute of Hajj Research, Makkah, Saudi Arabia
    Med Princ Pract 15:52-5. 2006
    ....
  78. ncbi In vitro inhibitory activities of essential oils from two Korean thymus species against antibiotic-resistant pathogens
    Seungwon Shin
    College of Pharmacy, Duksung Women s University, Seoul 132 714, Korea
    Arch Pharm Res 28:897-901. 2005
    ..Data from the checkerboard titer test confirmed synergism between the antibiotic, norfloxacin, and T. magnus oil or thymol, particularly against the resistant strains of S. aureus...
  79. ncbi Evaluation of the BIOCEN GC agar medium base in antimicrobial susceptibility testing of Neisseria gonorrhoeae
    Rafael Llanes
    Department of Bacteriology, Tropical Medicine Institute Pedro Kourí IPK, La Habana, Cuba
    Arch Med Res 36:344-9. 2005
    ..We evaluated three lots of GC agar medium base produced by BIOCEN, Cuba, in antibiotic susceptibility testing of reference and wild strains of gonococci...
  80. ncbi When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection
    Effie L Gillespie
    University of Connecticut, School of Pharmacy, Storrs, USA
    Conn Med 69:203-10. 2005
    ..Initial therapy should have a high likelihood of covering resistant pathogens...
  81. ncbi In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC
    Satoshi Yoshizumi
    Department of Microbiology, Toho University School of Medicine, Tokyo, Japan
    Chemotherapy 50:265-75. 2004
    ..The in vitro antimicrobial activities of new fluoroquinolones were tested against quinolone-resistant Haemophilus influenzae of clinical isolates...
  82. ncbi Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population
    Tadashi Shimoyama
    First Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, 036-8562, Hirosaki, Japan
    J Gastroenterol 39:927-30. 2004
    ..CONCLUSIONS: Lansoprazole-amoxicillin-metronidazole triple therapy is an effective and promising second-line H. pylori eradication therapy in a north Japanese population, which has a low frequency of metronidazole resistance...
  83. ncbi Application of glycodiversification: expedient synthesis and antibacterial evaluation of a library of kanamycin B analogues
    Jie Li
    Department of Chemistry and Biochemistry, Utah State University, 0300 Old Main Hill, Logan, Utah 84322-0300, USA
    Org Lett 6:1381-4. 2004
    ..reaction: see text] The expedient synthesis of a library of kanamycin B analogues is reported. The revealed SAR will guide future designs in developing kanamycin-type aminoglycoside antibiotics against drug-resistant bacteria...
  84. ncbi [Resistance phenotypes circulating in nosocomial high risk departments]
    Monica Licker
    Catedra de Microbiologie,
    Bacteriol Virusol Parazitol Epidemiol 47:173-8. 2002
    ..This leads us to the conclusion that antibiotic resistance pattern should be interpreted by the bacteriologist and a consistent policy concerning the use of antimicrobial drugs in hospital settings should be instituted...
  85. ncbi Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward
    Michael G Hughes
    Department of Surgery, University of Virginia, Charlottesville 22908, USA
    Crit Care Med 32:53-60. 2004
    ....
  86. ncbi Antibiotic resistance
    Thomas J Pallasch
    School of Dentistry, University of Southern California, Los Angeles, CA, USA
    Dent Clin North Am 47:623-39. 2003
    ....
  87. ncbi Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics
    Jun Wang
    Department of Human and Animal Infectious Disease, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Biol Chem 278:44424-8. 2003
    ....
  88. ncbi Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones
    Brijesh Kumar Srivastava
    Zydus Research Centre, Sarkhej Bavla N H 8A, Moraiya, Ahmedabad, Gujarat 382210, India
    Bioorg Med Chem Lett 17:1924-9. 2007
    ..The antibacterial activities were evaluated in standard in vitro MIC assay method. Some of the compounds showed in vitro (MIC) antibacterial activity comparable to those of Gatifloxacin, Ciprofloxacin, and Sparfloxacin...
  89. ncbi Drug-resistant Salmonella enterica serotype paratyphi A in India
    D S Chandel
    All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
    Emerg Infect Dis 6:420-1. 2000
    ..Paratyphi A abruptly increased in the New Delhi region. In the first 6 months of 1999, 32% of isolates were resistant to both chloramphenicol and cotrimoxazole and another 13% were resistant to more than two antibiotics...
  90. ncbi Antimicrobial susceptibility of intestinal bacteria from Swiss poultry flocks before the ban of antimicrobial growth promoters
    A Frei
    Department of Food Science, Swiss Federal Institute of Technology,
    Syst Appl Microbiol 24:116-21. 2001
    ..These data can be used as a baseline to determine antibiotic resistance rates after implementation of the growth promotor ban in 1999 in Switzerland...
  91. ncbi Management of fever in neutropenic patients
    G P Bodey
    Division of Internal Medicine, Section of Infectious Diseases, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    J Infect Chemother 7:1-9. 2001
    ..Although the prognosis for infection in neutropenic patients has improved greatly, new infectious problems have emerged that limit our successful management of these complications...
  92. ncbi Treatment and outcome of nocardia keratitis
    M S Sridhar
    Cornea Service, L.V. Prasad Eye Institute, Hyderabad, India
    Cornea 20:458-62. 2001
    ..In this small series, when appropriate therapy was initiated,Nocardia keratitis resolved promptly with good visual recovery...
  93. ncbi [Activity of cefepime compared with other antibiotics against major hospital bacterial pathogens]
    W Hryniewicz
    Centralne Laboratorium Surowic i Szczepionek w Warszawie
    Pol Merkur Lekarski 10:80-2. 2001
    ..A. baumannii was the least susceptible species (67.42%). This study indicate that cefepime may play an important role in therapy of nosocomial infections in particular caused by Enterobacteriace...
  94. ncbi Better control of antibiotic resistance
    D Guillemot
    , Villejuif, France
    Clin Infect Dis 33:542-7. 2001
    ....
  95. ncbi Antimicrobial susceptibility testing and patterns of resistance at a tertiary care center
    J Akhter
    Department of Microbiology, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia
    Saudi Med J 22:569-76. 2001
    ..In this review, we discuss patterns of susceptibility of different antimicrobials as experienced at King Faisal Specialist Hospital and Research Centre, a tertiary care center in Riyadh...
  96. ncbi Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB
    P Margolis
    Versicor, Inc, Fremont, California 94555, USA
    Antimicrob Agents Chemother 45:2432-5. 2001
    ..pneumoniae ATCC 49619 harbor mutations in defB but not in fmt. Reintroduction of the mutated defB gene into wild-type S. pneumoniae R6x recreates the resistance phenotype. The altered enzyme displays decreased sensitivity to actinonin...
  97. ncbi Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin
    U S Eggert
    Department of Chemistry, Princeton University, Princeton, NJ 08544, USA
    Science 294:361-4. 2001
    ..We identified a gene responsible for the susceptibility of Escherichia coli cells to killing by glycolipid derivatives of vancomycin, thus establishing a genetic basis for activity differences between these compounds and vancomycin...
  98. ncbi Mupirocin resistance among Malaysian isolates of methicillin-resistant Staphylococcus aureus
    A Norazah
    Division of Bacteriology, Institute for Medical Research, Jalan Pahang, 50588, Kuala Lumpur, Malaysia
    Int J Antimicrob Agents 17:411-4. 2001
    ..Even though the rate of mupirocin resistance in MRSA is still low in Malaysia, its presence calls for a strict policy on mupirocin usage in Malaysian hospitals...
  99. ncbi [Identification of microbial subtypes from antibiotic susceptibility data in clinical laboratory for nosocomial infection surveillance]
    K Sato
    Department of Medical Informatics, Kawasaki University of Medical Welfare, Kurashiki 701-0193
    Rinsho Byori 49:263-72. 2001
    ..This analysis is regarded as an "infotyping", in contrast to serotype or genotype, of clinical microbial isolates, which is useful for nosocomial infection surveillance...
  100. ncbi Enhanced antibacterial effect of erythromycin in the presence of 3,5-dibenzoyl-1,4-dihydropyridines
    G Gunics
    Faculty of Medicine, Institute of Microbiology, , Szeged, Hungary
    Anticancer Res 21:269-73. 2001
    ..Compound GB12 was the most effective in enhancing the activity of Er, and was selected for plasmid elimination studies. However, GB12 itself had no antiplasmid effect and did not alter the promethazine induced plasmid elimination...
  101. ncbi Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing
    F C Tenover
    Hospital Infections Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 39:241-50. 2001
    ....

Research Grants116 found, 100 shown here

  1. Antimicrobial Resistance in Bacteria
    Stanley Cohen; Fiscal Year: 2009
    ....
  2. RISK FACTORS FOR DRUG RESISTANT PNEUMOCOCCAL PNEUMONIA
    Joshua Metlay; Fiscal Year: 2003
    ..Finally, a cohort study will be completed within the study design, by examining outcomes for all patients, stratifying by pneumococcal drug susceptibility and adequacy of antimicrobial drug coverage. ..
  3. Advanced Infection Control methods for Antimicrobial Drug Resistance and Pathogen
    Christopher N Larsen; Fiscal Year: 2010
    ..This research will increase our understanding of microbial drug resistance, enable the tracking of new drug resistant organisms, and provide a measurement and surveillance utility ..
  4. Bi-functional Polymer-Attached Inhibitors of Influenza Viruses
    Jianzhu Chen; Fiscal Year: 2007
    ..that the proposed research will (i) yield one or more highly potent, optimized polymer-attached inhibitor(s) for future clinical development and (ii) provide a new paradigm of drug development for overcoming microbial drug resistance
  5. Antimicrobial Resistance in Bacteria
    Stanley N Cohen; Fiscal Year: 2010
    ....
  6. Molecular Detection of Blood Stream Infections in Women with Gynecologic Cancer
    JEANNE JORDAN; Fiscal Year: 2009
    ....
  7. Molecular Basis of Microbial Pathogenesis
    Randall Holmes; Fiscal Year: 2007
    ..b>Microbial drug resistance, emerging infections, use of microbes as bioterrorism weapons, and acquired immunodeficiency syndrome (..
  8. Pan Genomic Discovery of Genes Toxic to Bacteria
    Edward M Rubin; Fiscal Year: 2010
    ..This approach will be used to detect and develop new antimicrobial agents as well as study a new class of RNA molecules that are toxic to bacteria. ..
  9. Metabolic Drug Targeting in Haemophilus influenze
    CHRISTOPHE SCHILLING; Fiscal Year: 2004
    ..influenzae infections; 5) and enhanced validation of existing targets in H. influenzae. ..
  10. Epidemiology of imipenem-resistant P.aeruginosa
    Anthony Harris; Fiscal Year: 2007
    ..Aim 4: Determine the cost-effectiveness of three different infection control interventions. ..
  11. Mechanisms of Capsular Diversity in Streptococcus Pneumoniae
    Marc Lipsitch; Fiscal Year: 2007
    ....
  12. VACCINATION AND THE EVOLUTIONARY DYNAMICS OF PNEUMOCOCCI
    Marc Lipsitch; Fiscal Year: 2005
    ..abstract_text> ..
  13. New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission
    Anthony Harris; Fiscal Year: 2007
    ....
  14. Methodological Approaches to Planning and Analysis of N*
    Marc Lipsitch; Fiscal Year: 2007
    ..The goal of this work is to design tools that will aid in understanding and generalizing the output of computationally complex models of disease transmission. ..
  15. Study design importance in analyzing emerging pathogens
    Anthony Harris; Fiscal Year: 2005
    ..The second aim will be done by combining epidemiological relatedness and molecular relatedness through pulse-field gel electrophoresis of ESBL cultures to quantify the importance of patient to patient transmission. ..
  16. Epidemiologic Methods: Resistant Nosocomial Infections
    Marc Lipsitch; Fiscal Year: 2004
    ..This will in turn lead to better practices to reduce the incidence of ARNI. ..
  17. Epidemiology of emerging pathogens among hospitalizeds patients
    Anthony D Harris; Fiscal Year: 2010
    ..The reasons for the emergence of A. baumannii are unknown and no interventions have been successful at curbing this emergence. For these reasons, A. baumannii is a significant public health problem. ..
  18. Mechanisms of Capsular Diversity in Streptococcus Pneumoniae
    Marc Lipsitch; Fiscal Year: 2010
    ....
  19. Mechanisms of Capsular Diversity in Streptococcus Pneumoniae
    Marc Lipsitch; Fiscal Year: 2009
    ....
  20. Targeted Infection-control Program (TIP) to reduce Resistant Pathogens and Infect
    Lona Mody; Fiscal Year: 2010
    ..Molecular epidemiologic methods will trace the origin of resistant strains in nursing homes and further characterize newer strains of MDROs emerging and spreading in this often neglected setting. ..
  21. Training in Interdisciplinary Research to Reduce Antimicrobial Resistance (TIRAR)
    ELAINE LUCILLE LARSON; Fiscal Year: 2010
    ..These evaluationswill be a focal point of discussion in the Faculty Development Seminar, and suitable program modifications will be implemented by the Leadership Team. ..
  22. Structures of DNA and RNA Polymerases and Functional Complexes
    Thomas Steitz; Fiscal Year: 2007
    ..As the $29 DNA polymerase is homologous to those of several human pathogenic viruses, knowledge of its structure may yield insights into designing inhibitors of these pathogenic polymerases. ..
  23. Device use in Nursing Homes: Reducing Risk of Infection
    Lona Mody; Fiscal Year: 2007
    ..abstract_text> ..
  24. REGULATION OF AMPICILLIN RESISTANCE IN E FACEIUM
    Louis Rice; Fiscal Year: 2004
    ..They will also yield important new information on mechanisms of cell wall synthesis in E. faecium and other Gram-positive bacteria as well as on the mechanisms by which ampicillin resistance in E. faecium is regulated. ..
  25. REVERSE TRANSCRIPTASE AND OTHER HIV MOLECULAR STRUCTURES
    Thomas Steitz; Fiscal Year: 2002
    ..Crystallographic studies of both full length HIV integrase and the homologous transposase, TN552, complexed with suitable DNA substrates are aimed to produce mechanistic insights. ..
  26. Distribution of the Costs of Antimicrobial Resistant Infections
    ELAINE LUCILLE LARSON; Fiscal Year: 2010
    ..The analyses will match patients with resistant infections (hospital- and community-acquired) to susceptible patients and to uninfected patients. _^ ..
  27. Genetic Susceptibility to Mercury-Induced Immune Dysfunction in Autism & ASD
    Ellen Silbergeld; Fiscal Year: 2007
    ..Accomplishing the goals of this project will be the first stage in developing a broader study of gene-environment interactions in autism, as well as a targeted search for candidate genes related to mercury susceptibility in humans. ..
  28. Derivatization/Functionalization of Natural Product(RMI)
    Marvin Miller; Fiscal Year: 2007
    ..3. Broadly test the scaffold and derived libraries of novel compounds using the extensive set of assays in place at the Hans-Knoll Institute for Natural Products Research (HKI). ..
  29. PROPERTIES OF STREPTOCOCCAL M PROTEIN
    Vincent A Fischetti; Fiscal Year: 2010
    ....
  30. Design, Syntheses and Studies of Novel Antituberculosis Agents
    Marvin J Miller; Fiscal Year: 2010
    ....
  31. Chemistry-Biochemistry-Biology Interface Training Program at Notre Dame
    Marvin Miller; Fiscal Year: 2007
    ..Excellent research facilities equipped with state-of-the-art instrumentation Strong institutional commitment, with the University of Notre Dame providing a fellowship match in a 1:1 ratio and stipend supplementation of trainees ..
  32. Role of Genomic Imprinting in Developmental Neurotoxici*
    Ellen Silbergeld; Fiscal Year: 2003
    ..2. To utilize high throughput methods to examine patterns of DNA methylation in candidate genes in sperm and zygote in order to detect the presence of male-mediated effects on imprinted genes involved in early development. ..
  33. DNA GYRASE AND QUINOLONE RESISTANCE IN TUBERCULOSIS
    Karl Drlica; Fiscal Year: 1993
    ..tuberculosis and will begin to describe relationships between DNA supercoiling and virulence in M. tuberculosis. The work is expected to help guide efforts to develop new, more effective anti-tuberculosis agents...
  34. DNA GYRASE AND QUINOLONE RESISTANCE IN TUBERCULOSIS
    Karl Drlica; Fiscal Year: 2006
    ..abstract_text> ..
  35. Bioactive Compounds from Acylnitroso Cycloadducts
    Marvin Miller; Fiscal Year: 2006
    ..abstract_text> ..
  36. Regulation of Lipid Metabolism in Human Sebaceous Glands
    Diane Thiboutot; Fiscal Year: 2006
    ..Data generated from the proposed experiments will advance our understanding of the mechanisms regulating sebum production and can lead to identification of potential additional therapeutic target sites in the treatment of acne. ..
  37. Clinical Approaches to Ileal Pouch Dysfunction
    Bo Shen; Fiscal Year: 2005
    ..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
  38. Improving Antibiotic Use in Acute Care Settings
    Ralph Gonzales; Fiscal Year: 2006
    ..Specific Aim 2: To evaluate the impact of a rapid diagnostic test for c-reactive protein on antibiotic use for adults with acute cough illness when added to a multidimensional intervention. ..
  39. Minimizing Antibiotic Resistance in Colorado (MARC)
    Ralph Gonzales; Fiscal Year: 2004
    ..pneumoniae infections in and outside the intervention communities. Specific Aim IIIC: Conduct a net-cost analysis of the different levels of community education. ..